The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma.
The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials.
We have every reason to believe it will be effective with mesothelioma, too, Dr. Bernardo Goulart, chief trial investigator and medical oncologist at the Seattle Cancer Care Alliance (SCCA) told Asbestos.com. There is great logic behind it. We think this trial offers real hope for these patients.
Durvalumab activates a patients immune system to exert a cytotoxic response against tumor cells that overexpress the PD-L1 protein, which is common in several cancers, including mesothelioma.
The PD-L1 protein typically allows tumor cells to avoid a patients immune system.
This is the first time researchers test durvalumab in combination with chemotherapy in a first-line setting for mesothelioma. To qualify for this multicenter trial, patients must not have begun any other type of treatment.
Immunotherapy is going to play a big role in improving outcomes for these patients, Goulart said. After decades of no reasonable options, the future is looking brighter. Immunotherapy is one reason for that. This trial will help us help more patients.
U.S. News and World Report ranked SCCA among the top 10 Best Hospitals for Cancer Care in America in 2016. The hospital has made the list for more than a decade.
SCCA, which includes the University of Washington Medical Center and the Fred Hutchinson Cancer Research Center, has accelerated its role as a mesothelioma specialty center in recent years.
We want people to know that we are a center dedicated to treatment of this disease, Goulart said. We can offer options that other places just cant. I think we see this disease in a different way than others do.
The trial also is being held at other highly regarded cancer centers such as:
The primary purpose of the study is to determine whether adding durvalumab to pemetrexed and cisplatin or carboplatin will increase survival time. It also will measure response rate and progression-free survival.
Patients will be given the drug combination for six, three-week cycles. After completion, patients with stable or responding disease will then receive durvalumab alone every three weeks as maintenance until there is disease progression.
Other researchers are conducting two smaller studies on durvalumab to test its effectiveness with mesothelioma.
The Lung Institute at Baylor College of Medicine in Houston, which is headed by well-known mesothelioma specialist Dr. David Sugarbaker, is studying its effectiveness with surgery as a single agent and alongside tremelimumab, another type of immunotherapy drug.
The Dana Farber Cancer Institute in Boston is evaluating the effectiveness of the durvalumab/tremelimumab combination in second-line treatment for those with unresectable disease.
The multinational biopharmaceutical company AstraZenaca, based in Cambridge, England, markets durvalumab under the brand name Imfinzi.
The study of durvalumab, and other more well-known immunotherapy drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo), is critical to advancing treatment for mesothelioma. The FDA still has not approved any second-line treatment for the disease.
The first-line standard of care for mesothelioma remains a combination of surgery, chemotherapy and radiation, which hasnt changed in more than a decade.
An estimated 3,000 people annually in the United States are diagnosed with mesothelioma, which is typically traced to long-before occupational exposure to asbestos.
Some patients who come to us with mesothelioma already have been told by their doctor they have only 6-12 months to live, and there is nothing they can do, Goulart said. But there are options here. This trial is just one of those options.
See the original post here:
Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial - Asbestos.com
- Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers - Surviving Mesothelioma - March 24th, 2017 [March 24th, 2017]
- Republican Health Care Bill Includes Asbestos Exposure Funding for Libby Residents - Mesothelioma.com - March 24th, 2017 [March 24th, 2017]
- Pembrolizumab shows promise in treatment of mesothelioma - Science Daily - March 24th, 2017 [March 24th, 2017]
- Veterans with Mesothelioma Benefit from Telephone Triage - Asbestos.com - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Survival Rates Slowly Improving - Mesothelioma.net Blog (blog) - March 24th, 2017 [March 24th, 2017]
- Understanding Mesothelioma Caregiver Styles - Asbestos.com (blog) - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Patients Turn to Cannabis - AlterNet - March 24th, 2017 [March 24th, 2017]
- Mesothelioma | Overview, Treatment Options and Survivor Stories - March 24th, 2017 [March 24th, 2017]
- Accelerated Approval Granted to Drug in Mesothelioma Research Pipeline - MesotheliomaHelp.org (blog) - April 8th, 2017 [April 8th, 2017]
- New Study Affirms Mesothelioma Survival Benefit with Post-Surgical IMRT, According to Surviving Mesothelioma - Benzinga - April 8th, 2017 [April 8th, 2017]
- The Key to Mesothelioma Treatment Success with Immunotherapy - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- Shorter Mesothelioma Survival Linked to High Platelet Count - Asbestos.com - April 8th, 2017 [April 8th, 2017]
- Mesothelioma Victims Center Now Appeals to All Diagnosed ... - Yahoo Finance - April 8th, 2017 [April 8th, 2017]
- Early research suggests first immunotherapy for mesothelioma on the horizon - Medical Xpress - June 6th, 2017 [June 6th, 2017]
- Bristol-Myers Squibb's Opdivo, Yervoy put the brakes on mesothelioma in phase 2 - FiercePharma - June 6th, 2017 [June 6th, 2017]
- Methanol from African Plants Kills Mesothelioma Cells - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Mesothelioma Patients to be Celebrated on National Cancer Survivor's Day - Mesothelioma.net Blog (blog) - June 6th, 2017 [June 6th, 2017]
- IO Strategy In Mesothelioma Finally Gets Mapped Out | Seeking Alpha - Seeking Alpha - June 6th, 2017 [June 6th, 2017]
- New Blood Test Could Mean Earlier Mesothelioma Diagnosis - Surviving Mesothelioma - June 6th, 2017 [June 6th, 2017]
- Using Viruses to Boost Mesothelioma Immunotherapy - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Resilience Can Help Mesothelioma Patients and Their Families ... - MesotheliomaHelp.org (blog) - June 7th, 2017 [June 7th, 2017]
- Janet Stanton Schnitzer Remembers Her Father's Mesothelioma Battle - Mesothelioma & Asbestos Awareness Center (blog) - June 7th, 2017 [June 7th, 2017]
- Treating Mesothelioma: A rare, aggressive caner - ABC2 News - June 7th, 2017 [June 7th, 2017]
- Asbestos and Mesothelioma Lawsuits: What to Expect | Nolo.com - June 7th, 2017 [June 7th, 2017]
- Mesothelioma Victims Center Now Urges a Roofer/Insulator With Mesothelioma to Call About Why It Is Necessary to ... - PR Newswire (press release) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug - MesotheliomaHelp.org (blog) - June 9th, 2017 [June 9th, 2017]
- A Breath Test for Mesothelioma? - Surviving Mesothelioma - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer: 12 Essential Facts - Asbestos News - June 9th, 2017 [June 9th, 2017]
- Mesothelioma - NHS Choices - June 9th, 2017 [June 9th, 2017]
- 15-year Mesothelioma Survivor Living Life By Design - Asbestos.com (blog) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer Overview | Experienced Lawyers Here to Help - June 11th, 2017 [June 11th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Machinist to Call for Direct Access to Journeyman-Level ... - PR Newswire (press release) - June 12th, 2017 [June 12th, 2017]
- Honeywell Fails in Appeal Against Mesothelioma Verdict - Mesothelioma.net Blog (blog) - June 12th, 2017 [June 12th, 2017]
- Mesothelioma Patients Can See Improved Survival By Reporting Side Effects - MesotheliomaHelp.org (blog) - June 12th, 2017 [June 12th, 2017]
- What is Mesothelioma? | Surviving Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- Cases of Pleural Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- The Importance of Cancer Research in Immunotherapy - Mesothelioma.com (blog) - June 14th, 2017 [June 14th, 2017]
- Hopes High for Mesothelioma Immunotherapy Treatment ... - Mesothelioma.net Blog (blog) - June 14th, 2017 [June 14th, 2017]
- Asbestos Sprayers Face Higher Lifetime Mesothelioma Risk ... - Surviving Mesothelioma - June 14th, 2017 [June 14th, 2017]
- Remembering Loved Ones Lost to Mesothelioma, Looking Forward to Progress in Treatment - MesotheliomaHelp.org (blog) - June 14th, 2017 [June 14th, 2017]
- Chicago Public Schools Ignoring Asbestos Problem - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Length of Time Between Surgeries a Marker for Mesothelioma Survival - Surviving Mesothelioma - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Survivor Deals with Pain 15 Years After Surgery - Asbestos.com (blog) - June 16th, 2017 [June 16th, 2017]
- Nivolumab and Ipillimumab Show Promise in Treating Mesothelioma Recurrence - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients Should Heed FDA Warnings Regarding Miracle Cures - MesotheliomaHelp.org (blog) - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients May Benefit from Marijuana Research - Mesothelioma.net Blog (blog) - June 17th, 2017 [June 17th, 2017]
- The Challenges of Research in Immunotherapy - Mesothelioma.com (blog) - June 17th, 2017 [June 17th, 2017]
- Despite Mesothelioma Diagnosis, Dad Loved Father's Day - Asbestos.com (blog) - June 17th, 2017 [June 17th, 2017]
- I Want to Keep Writing About Mesothelioma and My Family's Journey Because It Matters - MesotheliomaHelp.org (blog) - June 17th, 2017 [June 17th, 2017]
- Mesothelioma Clinical Trial Opens with High Expectations - Asbestos.com - June 17th, 2017 [June 17th, 2017]
- Cediranib May be Safe Supplement to Mesothelioma Treatment - Surviving Mesothelioma - June 17th, 2017 [June 17th, 2017]
- New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma ... - Benzinga - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Symptoms - Identify Early Warning Signs - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Construction Worker or Plumber to Call for Instant Access to the ... - PR Newswire (press release) - June 20th, 2017 [June 20th, 2017]
- Mesothelioma Treatment May Benefit From New Discovery ... - Mesothelioma.net Blog (blog) - June 20th, 2017 [June 20th, 2017]
- The Influence of BAP1 on Mesothelioma Survival - Surviving Mesothelioma - June 20th, 2017 [June 20th, 2017]
- Clinical Trial to Assess If Radiation Therapy Can Bring Effective Relief from Mesothelioma Pain - MesotheliomaHelp.org (blog) - June 20th, 2017 [June 20th, 2017]
- Asbestos Exposure Attorneys - Mesothelioma Lawsuits ... - June 20th, 2017 [June 20th, 2017]
- Can a Breath Test Diagnose Mesothelioma in the Early Stages? - Asbestos.com - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Compensation Center Now Urges an Electric Utility Worker or Electrician with Mesothelioma to Aim High ... - PR Newswire (press release) - June 21st, 2017 [June 21st, 2017]
- Nurse Explains Mesothelioma Staging - MesotheliomaHelp.org (blog) - June 21st, 2017 [June 21st, 2017]
- 5 Questions: Treatment options exist for mesothelioma - Las Vegas Review-Journal - June 21st, 2017 [June 21st, 2017]
- Steve McQueen's Wife Pushes for Asbestos Ban - Mesothelioma.com - June 21st, 2017 [June 21st, 2017]
- Remembering Mesothelioma Victims in the UK - Mesothelioma.com (blog) - June 21st, 2017 [June 21st, 2017]
- Peritoneal Cancer Index: What it Means for Mesothelioma Patients - Mesothelioma & Asbestos Awareness Center (blog) - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure - Surviving Mesothelioma - June 21st, 2017 [June 21st, 2017]
- Nintedanib Combination Delayed Progression in Malignant Mesothelioma - Cancer Network - June 22nd, 2017 [June 22nd, 2017]
- Polish Study Confirms That Mesothelioma Risk Only Increases With ... - Mesothelioma.net Blog (blog) - June 22nd, 2017 [June 22nd, 2017]
- The Mesothelioma Victims Center Now Urges a Diagnosed Navy ... - PR Newswire (press release) - June 22nd, 2017 [June 22nd, 2017]
- Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment - MesotheliomaHelp.org (blog) - June 23rd, 2017 [June 23rd, 2017]
- Time Between Surgeries Helps Predict Mesothelioma Survival - Asbestos.com - June 23rd, 2017 [June 23rd, 2017]
- Testicular and Cardiac Mesothelioma - Surviving Mesothelioma - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Veterans Center - Access Benefits & VA Claims - June 23rd, 2017 [June 23rd, 2017]
- Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma ... - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Law Firm | Sokolove Law - June 23rd, 2017 [June 23rd, 2017]
- MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma - Surviving Mesothelioma - June 24th, 2017 [June 24th, 2017]
- Mesothelioma Survival Rate | Factors Affecting Survivorship - June 24th, 2017 [June 24th, 2017]
- Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma - Benzinga - June 26th, 2017 [June 26th, 2017]
- Symptoms of Mesothelioma - Critical Signs to Watch For - June 26th, 2017 [June 26th, 2017]